Procedure revenue fell 13.9% to $30.3 million, including an estimated $3.3 million impact from the recall. Peterson said procedure revenue was affected by lower volumes at existing clinics, procedure deferrals and pellet supply constraints associated with the recall. Asteria supplied approximately 30% of Biote’s shipped pellets during the second quarter, similar to the first quarter but down from more than 50% in the fourth quarter of 2025. Management expects procedure revenue to improve sequentially in both the third and fourth quarters, aided by more consistent supply and new-clinic growth. However, Peterson said procedure revenue is still expected to decline year over year in those periods, reflecting the first-half disruption and other near-term factors.